<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pentobarbital</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00312</strong>&#160; (APRD01174)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From <span class="caps">AMA</span> Drug Evaluations Annual, 1994, p236)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00312/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00312/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00312.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00312.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00312.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00312.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00312.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00312">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-ethyl-5-(1-methylbutyl)barbituric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-ethyl-5-(sec-pentyl)barbituric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pentobarbitone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pentobarbital Sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000442/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000442/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: QGMRQYFBGABWDR-UHFFFAOYNA-M</li>
              <li>Monoisotopic Mass: 248.113687095</li>
              <li>Average Mass: 248.254</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000442">DBSALT000442</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nembutal</td><td>Lundbeck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypnotics-and-sedatives">Hypnotics and Sedatives</a></li>
<li><a href="/mesh/adjuvants-anesthesia">Adjuvants, Anesthesia</a></li>
<li><a href="/mesh/gaba-modulators">GABA Modulators</a></li>
<li><a href="/mesh/barbiturates">Barbiturates</a></li></ul></td></tr><tr><th>CAS number</th><td>76-74-4</td></tr><tr><th>Weight</th><td>Average: 226.2722<br>Monoisotopic: 226.131742452</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WEXRUCMBJFQVBZ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCC(C)C1(CC)C(=O)NC(=O)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00312.gif?1265922773">show</a>(7.77 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Barbituric Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Ureides; Diazinanes; N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>ureide; 1,3-diazinane; carboxylic acid imide, n-unsubstituted; carboxamide group; secondary carboxylic acid amide; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the short-term treatment of insomnia.</td></tr><tr><th>Pharmacodynamics</th><td>Pentobarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.</td></tr><tr><th>Mechanism of action</th><td>Pentobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.</td></tr><tr><th>Absorption</th><td>Barbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>by hepatic microsomal enzyme system</p></td></tr><tr><th>Route of elimination</th><td>Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine, and less commonly, in the feces. Approximately 25 to 50 percent of a dose of aprobarbital or phenobarbital is eliminated unchanged in the urine, whereas the amount of other barbiturates excreted unchanged in the urine is negligible.</td></tr><tr><th>Half life</th><td>5 to 50 hours (dose dependent)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9156</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9713</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5926</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5947</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6155</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9218</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7789</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7066</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9086</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7484</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9301</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.711</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9522</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9276</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6789
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.89
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9603
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.2266 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9685
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8771
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ovation pharmaceuticals inc</li>
<li>Lannett co inc</li>
<li>Vitarine pharmaceuticals inc</li>
<li>Whiteworth towne paulsen inc</li>
<li>Anabolic inc</li>
<li>Elkins sinn div ah robins co inc</li>
<li>Everylife</li>
<li>Halsey drug co inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Parke davis div warner lambert co</li>
<li>L perrigo co</li>
<li>Purepac pharmaceutical co</li>
<li>Valeant pharmaceuticals international</li>
<li>Watson laboratories inc</li>
<li>Wyeth ayerst laboratories</li>
<li>Lundbeck inc</li>
<li>Nexgen pharma inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bpirx.com">Breckenridge Pharmaceuticals</a></li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.nexgenpharma.com">Nexgen Pharma Inc.</a></li>
<li>Professional Co.</li>
<li>RA Pharmaceuticals</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Pentobarbital sodium powder</td><td>27.0USD</td><td>g</td></tr><tr><td>Nembutal sodium 50 mg/ml via</td><td>20.65USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>129.5 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>679 mg/L (at 25 &#176;C)</td><td>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</td></tr><tr><td>logP</td><td>2.10</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>logS</td><td>-2.52</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>8.11 (at 25 &#176;C)</td><td>SERJEANT,EP &amp; DEMPSEY,B (1979)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>8.64e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.16</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.89</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>8.48</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>75.27</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>58</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>23.41</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Knodell RG, Spector MH, Brooks DA, Keller FX, Kyner WT: Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec;79(6):1211-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6777235">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00499" target="_blank">D00499 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07422" target="_blank">C07422 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4737" target="_blank">4737 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508399" target="_blank">46508399 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4575.html" target="_blank">4575 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=7983" target="_blank">7983 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL448" target="_blank">CHEMBL448 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000671" target="_blank">DAP000671 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450859" target="_blank">PA450859 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=141690" target="_blank">141690 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/pentob.htm" target="_blank">http://www.rxlist.com/cgi/generic2/pentob.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/pentobarbital.html" target="_blank">http://www.drugs.com/mtm/pentobarbital.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Pentobarbital" target="_blank">Pentobarbital <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N05CA01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N05#N05">N05 &#8212; PSYCHOLEPTICS</a></li><li><a href="/atc/N05C#N05C">N05C &#8212; HYPNOTICS AND SEDATIVES</a></li><li><a href="/atc/N05CA#N05CA">N05CA &#8212; Barbiturates, plain</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:24.04</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00312.pdf?1265922745">show</a>(50.3 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>The barbiturate, pentobarbital, decreases the effect of aminophylline.</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine. </td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The barbiturate, pentobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, pentobarbital, decreases the effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The barbiturate, pentobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid decreases the effect of anticonvulsant, pentobarbital.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>The barbiturate, pentobarbital, decreases the effect of griseofulvin.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenobarbital decreases the effect of levonorgestrel</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, megestrol.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The barbiturate, pentobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>The barbiturate, pentobarbital, decreases the effect of metronidazole.</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>The barbiturate, pentobarbital, decreases the effect of the calcium channel blocker, nifedipine.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>The barbiturate, pentobarbital, decreases the effect of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The anticonvulsant, pentobarbital, decreases the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Pentobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>The barbiturate, pentobarbital, decreases the effect of theophylline.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The barbiturate, Pentobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Pentobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Pentobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>